Therapeutic Equivalence of a Novel HFA134a-Containing Metered-Dose Inhaler and the Conventional CFC Inhaler (Berodual®) for the Delivery of a Fixed Combination of Fenoterol/ Ipratropium Bromide

Respiration

Volumn 64, Issue 4, 1997, Pages 273-280

  Maesen, Francis P V ^a   Greefhorst, Louis P M ^a   Smeets, Joseph J ^a   Wald, Frans D M ^b   Cornelissen, Piet J G ^b  

^a De Wever Hospital ^*  (Netherlands)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Asthma; Berodual and reg; ; Chlorofluorocarbon; Fenoterol ipratropium bromide fixed combination; HFA134a; Hydrofluoroalkane; Metered dose inhaler

Indexed keywords

FENOTEROL PLUS IPRATROPIUM BROMIDE; NORFLURANE; PROPELLANT;

ADULT; AGED; ARTICLE; ASTHMA; BIOEQUIVALENCE; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TIME; VERTIGO;

ADULT; AEROSOL PROPELLANTS; AGED; AIRWAY RESISTANCE; ASTHMA; BRONCHODILATOR AGENTS; CHLOROFLUOROCARBONS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FENOTEROL; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCARBONS, FLUORINATED; IPRATROPIUM; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; VITAL CAPACITY;

EID: 0030925251     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000196686     Document Type: Article

References (19)

1. Steed KP, Freund B, Towsc L, Newman SP: High lung deposition of fenoterol from Bi-NEB', a novel multiple dose nebuliser device, EurRespir J 1995;8(suppl 19):204s.
2. Maesen FPV, Smeets JJ, Smeets P, Wald FDM, Comelissen PJG: A pilot study to compare the efficacy and safety of fenoterol administered from an MDI with a metered dose solution from a novel device (BINEB*), Eur Respir J 1995;8(suppl 19):258s.
3. Leach CL: Approaches and challenges to use freon propellant replacements, Aerosol Sci Technol 1995;22:328-334.
4. l8F-labellcd and whole-body counting in healthy subjects, Am J Respir Crit Care Med I994;I49:A220.
5. Denver LH, Kirby SM, Olsson P, Ventresca GP: HFA!34a, a non-chlorinated propellant for use in metered-dose inhalers: Safely, tolcra-bility and blood pharmacokinetics in healthy volunteers, Br J Clin Pharmacol 1994:37:509.
6. Kirby SM, Smith J, Ventresca GP: Salmeterol inhaler using a non-chlorinated propellant, HFA134a: Systemic pharmacodynamic activity in healthy volunteers, Thorax 1995:50:679-681.
7. Taggart SCO, Custovic A, Richards DH, Woodcock A: GRI006642X: A new, nonozone depicting propellant for inhalers, Brit Med J 1995;310:639-640.
8. Dockhorn R, Vanden Burgt JA, Ekholm BP, Donnell D, Cullen MT: Clinical equivalence of a novel non-chlorofluorocarbon-containingsal-butamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma, J Allergy Clin Immunol 1995:96:50-56.
9. Spiers R, Klinger N, Ekholm B: Clinical effica-cy of salbutamo! CFC-free metered dose inhaler, Eur Respir J 1995;8(suppl 19):424s.
10. Klinger N, Ekholm B, Spiers R: Clinical safety of salbutamol CFC-free metered-dose inhaler, Eur Respir J 1995;8(suppl 19):424s.
11. Molkenboer JFWM, Comelissen PJG: A double-blind, randomised crossover study assessing the efficacy of Berodual' in comparison to its components ipratropium bromide and fcno-terol in chronic bronchitis, Postgrad Med J 1987;63(suppl 1): 19a.
12. Lavandier M, Bourcereau J, Jirou-Najou JL: Comparison of bronchodilating onset of action ofBerotec', Postgrad Med J 1987;63(suppl 1): 13a.
13. Elwood RK, Abboud RT: The short-term bron-chodilator effects of fenoterol and ipratropium in asthma, J Allergy Clin Immunol 1982:69: 467-473.
14. Maesen FPV, Boersma WG, Rammcloo RHU, Nosssnt GD, Molkenboer JFWM, Prins J, Wald FDM, Comelissen PJG: Dutch multicentre (6) double-blind parallel comparison of Beroduaf- (I00ng fenoterol + 40 ng ipratropium bromide) q.i.d, and salbutamol (200 ng) q.i.d, metered-dose inhaler after a single and chronic administration (90 days) in patients with chronic obstructive pulmonary disease, Eur Respir J 1991;4(suppl 14):931.
15. Haahtela T, Ahokas I, Ahoncn A, Assendclft van A, Havu M, Havu K, KavaT, Kotaniemi J, Monkare S, Valta R, Vilkka V: Inhaled bron-chodilators in asthma: Low or high dose? Ann Allergy 1991:66:175-180.
16. American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma, Am Rev Respir Dis 1987; 136:225-243.
17. Quanjer PhH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Ycmault J-C: Lung volumes and forced ventilatory flows, Report working party standardisation of lung function tests European Community for Steel and Coal, Official statement of the European Respiratory Society, Eur Respir J 1993;6(suppl 16):5-40.
18. Williams EJ: Experimental designs balanced for the estimation of residual effects of treatments, Austr J Sci Res 1949;series A2:149-168.
19. Westlake WJ: Response to TBL, Kirkwood: Bioequivalence testing - a need to rethink, Biometrics 1981:37:589-594.